Blood Monitored MRD Testing for NonSecretory Myeloma image

Blood Monitored MRD Testing for NonSecretory Myeloma

Jun 29, 2023
07:00PM - 08:00PM EDT
Online Event
Overview

Dr. Raj Chakraborty joins the Nonsecretory Myeloma Community to discuss blood-based MRD monitoring tests. How close are we to using them in clinic? What information or research still is needed? How could it affect monitoring of nonsecretory myeloma disease?

Agenda
7:00 PM
Introductions
Audrey Burton-Bethke

Audrey introduces the agenda of the event and our featured speaker Dr. Raj Chakraborty.

7:05 PM
Presentation
Dr. Rajshekhar Chakraborty

Dr. Raj Chakraborty discusses blood-based MRD monitoring tests. 

7:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Dr. Rajshekhar Chakraborty

Dr. Rajshekhar Chakraborty

Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic. Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.